Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Bavituximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT04150900Phase 2Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2020
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bavituximab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by University of Maryland, Baltimore. Started Jan 2020; status: active, not recruiting.
02
Drugs
bavituximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04150900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150900.